About: IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Creator	Ding, Xianting Hanson, Brendon Le, Nguyen Chan, Conrad Blasiak, Agata Desai, Rishi Ho, Dean Hooi, Lissa Kee, Theodore Truong, Anh Gek, Shirley Seah, Kheng Chow, Kai-Hua Chye, De Lim, Jhin Remus, Alexandria Wong, San
Source	MedRxiv
abstract	The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) has led to the rapid initiation of urgently needed clinical trials of repurposed drug combinations and monotherapies. These regimens were primarily relying on mechanism-of-action based selection of drugs, many of which have yielded positive in vitro but largely negative clinical outcomes. To overcome this challenge, we report the use of IDentif.AI, a platform that rapidly optimizes infectious disease (ID) combination therapy design using artificial intelligence (AI). In this study, IDentif.AI was implemented on a 12-drug candidate therapy search set representing over 530,000 possible drug combinations. IDentif.AI demonstrated that the optimal combination therapy against SARS-CoV-2 was comprised of remdesivir, ritonavir, and lopinavir, which mediated a 6.5-fold improvement in efficacy over remdesivir alone. Additionally, IDentif.AI showed hydroxychloroquine and azithromycin to be relatively ineffective. The identification of a clinically actionable optimal drug combination was completed within two weeks, with a 3-order of magnitude reduction in the number of tests typically needed. IDentif.AI analysis was also able to independently confirm clinical trial outcomes to date without requiring any data from these trials. The robustness of the IDentif.AI platform suggests that it may be applicable towards rapid development of optimal drug regimens to address current and future outbreaks.
has issue date	2020-05-08(xsd:dateTime)
bibo:doi	10.1101/2020.05.04.20088104
has license	medrxiv
sha1sum (hex)	d1a5f5601ec8e1e2b04ffb93d461ae6c842e6ded
schema:url	https://doi.org/10.1101/2020.05.04.20088104
resource representing a document's title	IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
resource representing a document's body	covid:d1a5f5601ec8e1e2b04ffb93d461ae6c842e6ded#body_text
is schema:about of	named entity 'coronavirus disease 2019' covid:arg/d1a5f5601ec8e1e2b04ffb93d461ae6c842e6ded named entity 'repurposed' named entity 'optimizes' named entity 'initiation' named entity 'selection' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'emergence' named entity 'Artificial Intelligence' named entity 'Remdesivir' named entity 'SARS-CoV-2' named entity 'lopinavir' named entity 'combination therapy' named entity 'Lopinavir' named entity 'Remdesivir' named entity 'COVID-19' named entity 'clinical investigation' named entity 'drug interactions' named entity 'LPV' named entity 'Vero E6' named entity 'virus' named entity 'preprint' named entity 'azithromycin' named entity 'MOA' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'infection' named entity 'Vero E6' named entity 'remdesivir' named entity 'preprint' named entity 'F-test' named entity 'United States Food and Drug Administration' named entity 'standard of care' named entity 'clinical trials' named entity 'EC50' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'data set' named entity 'lopinavir' named entity 'ritonavir' named entity 'cytotoxicity' named entity 'drug combination' named entity 'AZT' named entity 'antiviral activity' named entity 'P-values' named entity 'peer review' named entity 'preprint' named entity 'drug interactions' named entity 'peer review' named entity 'comorbidities' named entity 'combination therapy' named entity 'Singapore' named entity 'peer review' named entity 'ritonavir' named entity 'D.H.' named entity 'pathogens' named entity 'infection' named entity 'efficacies' named entity 'actionability' named entity 'agnostic' named entity 'peer review' named entity 'preprint' named entity 'critical role' named entity 'parameter space' named entity 'preprint' named entity 'preclinical' named entity 'remdesivir' named entity 'potential treatments' named entity 'clinical trials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software